副鼻腔炎に対するAspoxicillinの薬効評価

抄録

We conducted a clinical study on Aspoxicillin (ASPC, TA-058), a newly synthesized penicillin, in paranasal sinusitis and the following results were obtained. 1) The clinical response was obtained in 59.2% (29/49) as judged by doctors in charge. 2) Based on the criteria of the evaluation committee, the clinical response was obtained in 60.5% (26/43). 3) Bacteriologically, the percentage eradication of causal organisms was 79.5% (35/44). 4) Adverse reaction was observed in 1 of the 63 cases (1.6%). From the above findings, it is presumed that ASPC is an useful antibiotic for the treatment for paranasal sinusitis.